Focus on Optimized Dosing of Ibrutinib Panel Discussion

First International Summit on Interventional Pharmacoeconomics

The Interventional Pharmacoeconomic Toolbox Panel Discussion

Opportunities to Optimize Cancer Policies Panel Discussion

Clifford A. Hudis, MD, and Allen S. Lichter, MD, on Oncology Drug Pricing in the United States: What You Need to Know

Allen S. Lichter, MD, of the Value in Cancer Care Consortium, interviews Clifford A. Hudis, MD, Chief Executive Officer of ASCO, on the question of whether cancer drug prices in the United States are the problem, or just the symptom, of a larger systemic issue.

Amit Sanyal, MD: A Clinician’s Perspective

Issues in Oncology

The ASCO Post Staff

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Deborah Schrag, MD, MPH, of Dana-Farber Cancer Institute, offers her perspective on near-equivalence, Bayesian noninferiority, and the value of cancer drug optimization.

Nov

Today In Oncology

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Related Videos

The Interventional Pharmacoeconomic Toolbox Panel Discussion

Opportunities to Optimize Cancer Policies Panel Discussion

Clifford A. Hudis, MD, and Allen S. Lichter, MD, on Oncology Drug Pricing in the United States: What You Need to Know

Amit Sanyal, MD: A Clinician’s Perspective

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Study Finds Personalized Risk Messages Had No Effect in Raising Colorectal Cancer Screening Participation

My 50 Years in Lymphoma: Lessons Learned?

Does Kidney Stone History Impact Survival Outcomes in Upper Tract Urothelial Carcinoma

Active Surveillance With Metformin vs Placebo in Low-Risk Prostate Cancer

Izalontamab Brengitecan in Recurrent or Metastatic Nasopharyngeal Carcinoma